Ultime notizie per Envista Holdings (NYSE:NVST) Azioni

Envista Holdings

Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments comprising Specialty Products and Technologies and Equipment and Consumables. The Company's Specialty Products & Technologies segment develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. The Company's Equipment & Consumables segment manufactures dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems.

Envista Holdings Corporation Common Stock

Envista Holdings Corp

WIIM

PRZO

ParaZero shares are trading higher after the company received Israel Ministry of Defense approval for the marketing of its  C-UAS.

Permian Resources shares are trading higher after Morgan Stanley initiated coverage on the stock with an Overweight rating and $19.

The most oversold stocks in the materials sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Mp Materials Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>)</h3>
<ul>
<li>On Dec. 9, MP Materials announced exchanges of a portion of its 0.25% green convertible senior notes due 2026, representing a net reduction of $25 million of outstanding indebtedness. The company' stock fell around 1% over the past month and has a<a href="https://www.benzinga.com/quote/MP"> 52-week low of $10.02</a>.</li>
<li>RSI Value: 29.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>MP Price Action: Shares of MP closed at $19.38 on Wednesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1">latest MP news</a>. </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/33b2eabd-d190-4861-894a-21adfadc832c" alt="" style="width:677px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Aptargroup Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATR#NYSE">ATR</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Jan. 7, Raymond James analyst Matt Roberts initiated coverage on AptarGroup with an Outperform rating and announced a price target of $200. The company's stock fell around 10% over the past month and <a href="https://www.benzinga.com/quote/ATR">has a 52-week low</a> of $124.94.</li>
<li>RSI Value: 28.6</li>
<li>ATR Price Action: Shares of Aptargroup closed at $154.15 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1">ATR stock</a>. </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/5e2009b7-bacf-4c30-8efa-8883d6f10ec9" alt="" style="width:640px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Westlake Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>)</h3>
<ul>
<li>On Jan. 7, Piper Sandler analyst Charles Neivert maintained Westlake with an Overweight and lowered the price target from $155 to $135.. The company's stock fell around 10% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/wlk">low of $108.95.</a></li>
<li>RSI Value: 19.8</li>
<li>WLK Price Action: Shares of Westlake fell 0.1% to close at $110.54 on Wednesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"> WLK shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="852" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10085621/image-58.png" alt="" class="wp-image-728154" style="width:645px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10085621/image-58.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10085621/image-58-300x283.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10085621/image-58-768x725.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
Read This Next:<a href="https://www.benzinga.com/25/01/42900074/how-to-earn-500-a-month-from-synovus-financial-stock-ahead-of-q4-earnings"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/01/42900074/how-to-earn-500-a-month-from-synovus-financial-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Synovus Financial Stock Ahead Of Q4 Earnings</a></li>
</ul>

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

Top 3 Materials Stocks That Are Set To Fly This Month

Wells Fargo analyst Ike Boruchow maintains TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) with a Equal-Weight and raises the price target from $115 to $120.

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on TJX Companies, Raises Price Target to $120

Wells Fargo analyst Ike Boruchow maintains Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Equal-Weight and raises the price target from $215 to $225.

Wells Fargo Maintains Equal-Weight on Ralph Lauren, Raises Price Target to $225

ParaZero Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRZO#NASDAQ">PRZO</a>) (the "company" or "ParaZero"), an aerospace company focused on safety systems for commercial unmanned aircrafts and defense Counter UAS systems, announced today that it has received official approval from the Israeli Defense Export Controls Agency (DECA) under the Ministry of Defense (MOD) for the marketing of its cutting-edge Counter-Unmanned Aerial Systems (C-UAS) solution. This milestone marks a significant step in ParaZero's efforts to expand its presence in the global defense and security markets.
The company's counter-drone system, The DefendAir by ParaZero, leverages ParaZero's proprietary technology to intercept unauthorized or hostile drones, providing a robust last-line of defense for critical infrastructure, sensitive military operations, and public safety. With DECA approval, ParaZero is now authorized to market and deploy this innovative solution to international customers, including governments, defense organizations and private enterprises.

Global

ParaZero Has Received Official Approval From The Israeli Defense Export Controls Agency Under The Ministry Of Defense For The Marketing Of Its Counter-Unmanned Aerial Systems Solution

Silynxcom Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYNX#NYSE">SYNX</a>) ("Silynxcom" or the "Company"), a manufacturer and developer of ruggedized tactical communication headset devices, today announced preliminary unaudited year-end financial results for the twelve months ended December 31, 2024.
On a preliminary unaudited basis, Silynxcom is reporting a strong performance for 2024, highlighting accelerated operational and business growth including:
<ul>
<li>Revenue estimated at $9.2 million in 2024, representing an increase of more than 20% compared to 2023; and &nbsp;</li>
<li>Cash and cash equivalents as of December 31, 2024 totaled $3.2 million.</li>
</ul>

Earnings

SYNX

Silynxcom Reports FY24 Revenue Of ~$9.2M, An Increase Of More Then 20% YoY

Wells Fargo analyst Ike Boruchow maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Equal-Weight and raises the price target from $170 to $215.

DECK

Wells Fargo Maintains Equal-Weight on Deckers Outdoor, Raises Price Target to $215

HC Wainwright &amp; Co. analyst Edward White reiterates Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) with a Buy and maintains $4 price target.

Reiteration

SNSE

HC Wainwright & Co. Reiterates Buy on Sensei Biotherapeutics, Maintains $4 Price Target

XTIA

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Macro Economic Events

Macro Notification

Economics

General

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are lower following better-than-expected US employment data.

Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) is trading higher amid a sharp increase in its <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42805470/shiba-inus-2133-burn-rate-surge-followed-by-10-price-rise-whats-happening#:~:text=Shiba%20Inu's%202%2C133%25%20Burn%20Rate,%2D%20Benzinga">token burn rate</a> and anticipation surrounding the launch of the TREAT token on Jan. 14.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00002165</td>
<td>$12.8 billion</td>
<td>+2.6%&nbsp;</td>
<td>-7%&nbsp;</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.3337</td>
<td>$49.3 billion</td>
<td>+1.5%&nbsp;</td>
<td>-4.3%</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>&nbsp;$0.00001772</td>
<td>$7.5 billion</td>
<td>+1.5%&nbsp;</td>
<td>-14%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Javon Marks observed that Shiba Inu is maintaining its post-breakout momentum, signaling the potential for further gains. 
He stated that the slower pace of the current rally might actually support its longevity and scale. 
"The sustained momentum suggests this run may not be over yet," Marks tweeted.
Marks identified $0.000081 as the next key resistance level, which would be a 261% gain from current prices. 
Surpassing this level could set the stage for a move toward $0.0001553.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Usually, you give dogs treats, but this <a href="https://twitter.com/search?q=%24SHIB&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SHIB</a> (Shiba Inu) looks like its going to be giving us one as its priced continue to hold significant post-breakout gains in a run that can be far from concluded &#x1f415;! Still being broken out, the target remains over +261% away at $0.000081… <a href="https://t.co/l1fyji0lDb">https://t.co/l1fyji0lDb</a> <a href="https://t.co/XmlO6wOWv2">pic.twitter.com/XmlO6wOWv2</a>
&mdash; JAVON&#x26a1;&#xFE0F;MARKS (@JavonTM1) <a href="https://twitter.com/JavonTM1/status/1877393141621228017?ref_src=twsrc%5Etfw">January 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Statistics: Shibburn data indicates that in the past 24 hours, 27.99 million SHIB tokens were burned, including a 17.2 million SHIB burn in a single transaction, followed by another 4.6 million burn. 
This spike represents a 5,895.9% increase in the burn rate, reducing token supply and boosting scarcity.
According to IntoTheBlock, five wallets control 57% of the total SHIB supply, with one wallet alone holding 41.7%. 
Such concentrated holdings amplify the likelihood of market volatility, as significant movements in these wallets could disrupt price stability.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/top-stories/25/01/42898917/dogecoin-killer-shiba-inu-down-3-5-in-7-days-is-this-really-healthy-accumulation">&#8216;Dogecoin Killer&#8217; Shiba Inu Down 3.5% In 7 Days: Is This Really &#8216;Healthy Accumulation&#8217;?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Shiba Inu Burns 28 Million Tokens, Rises 2%: What Is Going On?

The online dating industry may have hit its roughest patch yet. With <a href="https://www.benzinga.com/topic/online-dating">global online dating</a> spend flatlining at a projected 0% growth in 2025, JPMorgan analyst Cory Carpenter sees stagnation stemming from a lack of innovation and waning interest among younger users. 
While AI promises a future of smarter matchmaking, Carpenter believes turnaround efforts at Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) and Bumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) are still in their early days, signaling a challenging year ahead.
<h2 class="wp-block-heading">Match Group: Tinder Turnaround Stumbles</h2>
<ul>
<li>Rating: Neutral</li>
<li>Price Target: $33</li>
<li>Upside: Margin expansion amid declining revenue</li>
</ul>
Match's marquee app, Tinder, continues to face payer declines despite ambitious AI-driven product roadmaps. With a return to revenue growth not expected until 2027, the near-term outlook remains grim. Carpenter highlights Tinder's ongoing struggles to stabilize user and revenue trends, noting, &#8220;Tinder's turnaround will likely take years, and hedge funds remain cautious.&#8221;
Key catalysts for 2025 include biometric screening tests, AI-enabled discovery features, and potential activist pressure. Despite a 2.4% dividend yield and promising margin-focused strategies, investor skepticism looms.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/downgrades/24/12/42561430/match-group-analyst-flags-tinder-woes-industry-challenges-for-stock-downgrade">Match Group Analyst Flags Tinder Woes, Industry Challenges For Stock Downgrade</a>
<h2 class="wp-block-heading">Bumble: Slow Burn In A Turnaround</h2>
<ul>
<li>Rating: Neutral</li>
<li>Price Target: $8</li>
<li>Upside: Modest buyback potential, M&amp;A opportunities</li>
</ul>
Bumble's pivot to reinvigorate growth is off to a rocky start, with 2024&#8217;s app relaunch falling flat. Revenue is expected to decline again in 2025, with key competitor Hinge continuing to gain ground. 
Carpenter remains unconvinced by Bumble's upcoming product features, stating they &#8220;feel more incremental than transformative.&#8221;
The winter product release, featuring innovations like AI-powered photo selection and ID verification, offers only a glimmer of hope amid uncertainty. Management's focus on ecosystem strengthening and customer experience innovation may need more time to show meaningful results.
<h2 class="wp-block-heading">Industry Shake-Up Coming?</h2>
Despite dim short-term prospects, Carpenter sees potential for industry consolidation, though he remains skeptical about near-term take-private deals.
The dating industry's next chapter might hinge on bold AI-driven product innovation or game-changing mergers to reignite growth.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42783632/bumble-shares-tumble-by-45-in-2024-cfo-exit-competition-and-slowing-industry-growth-prompt-analyst-to-downgrade-the-stock">Bumble Shares Tumble By 45% In 2024: CFO Exit, Competition And Slowing Industry Growth Prompt Analyst To Downgrade The Stock</a></li>
</ul>
Photo: Shutterstock

Analyst Color

BMBL

MTCH

Match Group, Bumble's Growth Stalls: Analyst Warns Of Challenging 2025

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) with a Buy and maintains $2 price target.

PHGE

HC Wainwright & Co. Reiterates Buy on BiomX, Maintains $2 Price Target

Wells Fargo analyst Daniel Politzer upgrades Wyndham Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WH#NYSE">WH</a>) from Equal-Weight to Overweight and raises the price target from $103 to $114.

Upgrades

Wells Fargo Upgrades Wyndham Hotels & Resorts to Overweight, Raises Price Target to $114

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) with a Buy and maintains $10 price target.

CMPX

HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $10 Price Target

ON Semiconductor shares are trading lower after Truisit Securities downgraded the stock from Buy to Hold and lowered its price target from $85 to $60.

RPRX

Royalty Pharma shares are trading higher after the company announced it increased its quarterly dividend.

Guidance

IRMD

IRADIMED Reports Prelim. Q4 Revenue $19.2M-$19.4M, Prelim. FY24 Revenue $73.1M-$73.3M

On Friday, Walgreens Boots Alliance Inc&nbsp;(NASDAQ:&nbsp;WBA) reported first-quarter sales of $39.46 billion, up 7.5% year over year (+6.9% on constant currency), beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $37.28 billion</a>, reflecting sales growth across all segments.
Adjusted operating income&nbsp;was $593 million compared to adjusted operating income of $687 million in the year-ago quarter, reflecting lower U.S. retail sales and lapping prior year sale-leaseback gains, partly offset by cost savings initiatives and growth in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42908835/walgreens-boots-alliance-reports-fiscal-2025-first-quarter-results" rel="noreferrer noopener">U.S. Healthcare segment</a>.
Adjusted EPS was&nbsp;$0.51, down from $0.66 a year ago, beating the consensus of $0.37, according to data from&nbsp;<a target="_blank" href="https://benzinga.grsm.io/register174" rel="noreferrer noopener">Benzinga Pro</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42823134/walgreens-faces-strategic-challenges-amid-analysts-cautious-optimism" rel="noreferrer noopener">Walgreens Faces Strategic Challenges, Analysts Are Cautiously Optimistic</a>
The U.S. Retail Pharmacy segment sales reached $30.9 billion, up 6.6%. Comparable sales increased 8.5%.
Pharmacy sales increased by 10.4%, and comparable pharmacy sales increased by 12.7%, driven by higher branded drug inflation and prescription volume.
Comparable prescriptions increased by 2.3%, and prescriptions excluding immunizations increased by 3.5% compared to a year ago.
Total prescriptions filled in the quarter, including immunizations, increased 1.5% to 316.3 million.
Retail sales decreased 6.2%, and comparable retail sales decreased 4.6% compared with the year-ago quarter,&nbsp;mirroring a weaker cough cold flu season and lower sales in discretionary categories.
The U.S. Healthcare&nbsp;segment's sales were&nbsp;$2.2 billion. VillageMD sales increased 9%, CareCentrix sales increased 16%, and Shields sales rose 30%.
Guidance:&nbsp;Walgreens Boots Alliance maintains fiscal 2025 adjusted EPS&nbsp;guidance of $1.40 &#8211; $1.80 versus the consensus of $1.52.
The company <a target="_blank" href="https://investor.walgreensbootsalliance.com/static-files/b93516a3-ac11-4bf3-af48-08739983eaaf" rel="noreferrer noopener">expects</a> growth in U.S. Healthcare and International offset by pressure in U.S. Retail Pharmacy largely driven by weaker retail front end performance.
Price Action: WBA stock is up 16.3% at $10.72 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42910243/kkr-and-psp-secure-199-stake-in-american-electric-for-282b" target="_blank" rel="noreferrer noopener">American Electric Power Sells 19.9% Stake In Two Transmission Assets For $2.82B: Details</a></li>
</ul>
Image via Shutterstock.

Equities

Health Care

Movers

Walgreens Boots Alliance Stock Jumps On Better Than Expected Q1 Earnings, Sticks To Annual Profit Forecast

Stifel Nicolaus analyst Jonathan Block maintained a Buy rating on Envista Holdings (NVST – Research Report) yesterday and set a price target of $24...

Stifel Nicolaus Remains a Buy on Envista Holdings (NVST)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY – Research Report) and Envista Holdings...

Analysts Conflicted on These Healthcare Names: Bristol-Myers Squibb (BMY) and Envista Holdings (NVST)

Assessing MedTech impact from potential China tariffs

BlackRock Event Driven Equity Fund Q3 2024 Commentary

Mizuho analyst Steven Valiquette initiated coverage of Envista (NVST) with an Underperform rating and $20 price target As a diverse dental/orthodon...

Envista initiated with an Underperform at Mizuho

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

GE Vernova initiated, Merck upgraded: Wall Street's top analyst calls

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cartesian Therapeutics (RNAC – Research Report), E...

Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC), Envista Holdings (NVST) and UnitedHealth (UNH)

Tracking John Rogers' Ariel Investments Portfolio - Q3 2024 Update

NeuroPace (NPCE) announced the appointment of Scott Huennekens to its board of directors, effective January 6. Huennekens currently serves as chair...

NeuroPace appoints Scott Huennekens to board

Analyst Jonathan Block of Stifel Nicolaus maintained a Buy rating on Envista Holdings (NVST – Research Report), retaining the price target of $24.0...

Envista Holdings: Positive Momentum and Financial Strengthening Under New Management

ALEC

ALGN

BOKF

CHKP

COHR

CPRI

CTLT

DOCS

GDRX

GEHC

GNRC

GNTX

HSIC

HYPR

LFMD

MASI

MGRB

MGRD

MGRE

MSFT

MSGE

MSGS

NISTF

NONOF

NPCE

NPSCY

NTRS

NTRSO

NVST

PDCO

PSTG

REZI

RNAC

SAEF

SOLV

SPHR

TALK

TNDM

TRMB

VEEV

VLTO

XRAY

ZBRA

Press Releases

Envista Announces Participation in Baird's 2024 Global Healthcare Conference

DEXIS Digital Ecosystem Expands With Three New Innovations To Streamline and Connect Dental Workflows

Envista Schedules Third Quarter 2024 Earnings Call

Envista Reports Third Quarter 2024 Results

Envista Announces Participation in Evercore HealthCONx Conference

Commodities

Envista Announces Release of 2023 Sustainability Report

Events

DEXIS Attends ADF, Showcases Award-Winning Solutions

QuidelOrtho Announces Appointment of Two Independent Directors to its Board

Envista Announces Participation in 43rd Annual J.P. Morgan Healthcare Conference

Management

NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates

Comments

Envista Holdings

Notizie

Ultime notizie per Envista Holdings (NYSE:NVST) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO